GSK598809

DRUG8 trials

Sponsors

GlaxoSmithKline, Massachusetts General Hospital

Conditions

Alcohol DependenceNicotine DependenceSubstance Dependence

Phase 1

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

CompletedNCT00437840

GlaxoSmithKlineSubstance Dependence

Start: 2007-03-20End: 2007-06-20Updated: 2017-08-07

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

CompletedNCT00437632

GlaxoSmithKlineSubstance Dependence

Start: 2007-03-01End: 2008-08-22Updated: 2017-07-31

A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward

CompletedNCT00605241

GlaxoSmithKlineSubstance Dependence

Start: 2008-02-25End: 2009-03-20Updated: 2017-07-21

A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers

CompletedNCT00728052

GlaxoSmithKlineSubstance Dependence

Start: 2008-06-09End: 2008-08-19Updated: 2017-08-03

EtOH Interaction Study

CompletedNCT00887367

GlaxoSmithKlineSubstance Dependence

Start: 2008-09-29End: 2008-12-03Updated: 2017-07-18

Effects of GSK598809 on Brain Activation in Abstinent Alcoholics

WithdrawnNCT00908206

GlaxoSmithKlineAlcohol Dependence, Substance Dependence

Start: 2009-05-31End: 2009-07-31Updated: 2015-04-17

Phase 2

Relapse Prevention Study in Newly Abstinent Smokers

WithdrawnNCT00793468

GlaxoSmithKlineSubstance Dependence

Start: 2008-12-31End: 2008-12-31Updated: 2016-02-15

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

CompletedNCT01188967

Massachusetts General HospitalNicotine Dependence

Start: 2010-08-31End: 2013-05-31Updated: 2017-02-23